期刊文献+

均相体系合成苯扎贝特的工艺研究

Synthetic Technology of Benzafibrate in Homogeneous System
下载PDF
导出
摘要 以Na OH水溶液代替固体Na OH,在均相体系中合成目标化合物。以BZ收率和含量为指标,考察了Na OH用量和浓度、滴加CHCl3前混合搅拌时间等因素对反应的影响,并通过正交实验得出该工艺的最佳条件。结果表明:当Na OH浓度在55%时,BZ粗品收率和含量分别可由原工艺的95.6%和94.5%提高到98.9%和97.2%,且回收的丙酮不需精馏脱水即可循环使用。该工艺操作简单,避免了严格的无水条件和因Na OH粉碎造成的粉尘污染和腐蚀,更适用于贝特类药物及其相似结构化合物的工业化生产。 Benzafibrate( BZ),the hypolipidemic drug,was prepared in homogeneous system with Na OH aqueous solution instead of Na OH solid. Evaluated by the yield and content of BZ,the effect of the concentration and amount of Na OH,the stirring time before the CHCl3 addition were investigated. The optimum conditions of the reaction were obtained by orthogonal experiment. Compared to the original technology,the yield and content of the BZ increased from 95. 6% and 94. 5% to 98. 9% and 97. 2%,respectively,when the reaction occurred in the homogeneous system with 55%( w / w) Na OH solution. The recovered acetone can be reused without dehydration by distillation. The improved process can be applied to large-scale synthesis of other fibrate drugs and the compounds with similar structure for its simple operation and green technology. The dust pollution and corrosion caused by Na OH grinding together with the strict anhydrous conditions is also avoided.
出处 《化学试剂》 CAS 北大核心 2015年第11期1043-1046,共4页 Chemical Reagents
基金 江苏省科技厅产学研联合创新资金项目(BY-2013052) 淮安市产学研合作促进计划项目(HC201207)
关键词 苯扎贝特 均相体系 合成工艺 benzafibrate homogeneous system synthetic technology
  • 相关文献

参考文献11

二级参考文献55

  • 1郁铭,付春.对羟基苯乙胺合成技术进展[J].精细与专用化学品,2004,12(12):5-7. 被引量:7
  • 2吴洁.苯扎贝特合成过程中的杂质分离及工艺改进[J].中国现代应用药学,2006,23(4):301-302. 被引量:2
  • 3吕国平,郑智慧,赵宝华,向四海,董悦生,王富强,张华.PPARδ激动剂高通量筛选模型的建立[J].生物工程学报,2007,23(2):343-346. 被引量:7
  • 4Inaba T,Yagyu H, Itabashi N, et al. Cholesterol reduction and ather- osclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice[ J]. Hypertens Res,2008,31 (5) :999 - 1005.
  • 5Tenenbaum A, Motro M, Fisman EZ, et al. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease [ J ]. Circulation ,2004,109:2197 - 2202.
  • 6Arcavi L, Behar S, Caspi A, et al. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study[ J]. Am Heart J ,2004,147 ( 2 ) :239 - 245.
  • 7Hrebicek J. PPARs:the role in glucose and lipid homeostasis,insulin resistance and atherosclerosis[ J]. Cesk Fysiol,2004,53 ( 1 ) : 4-16.
  • 8Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors ( PPAR ) co-agonism : the bezafibrate lessons [ J ]. C ardiovasc Diabetol, 2005,16 ( 4 ) : 14.
  • 9Nagasawa T, Inada Y, Nakano S, et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet European[ J]. J Pharmacology,2006,536( 1 -2) :182 - 191.
  • 10Nakano S, Inada Y, Masuzaki H, et al. Bezafibrate regulates the expression and enzyme activity of 11 β-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 333-L1 adipocytes [ J]. Am J Physiol Endocrinol Metab,2007,292(4) :E1213 -E1222.

共引文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部